by Katherine Allen; From Science 2.0 to Pharma 3.0. Posted on July 29, 2013.
“As a librarian in a large pharmaceutical company, Hervé Basset has a perspective both on drug manufacturers and consumers of scientific information. In this book he aims to explore the profound changes that are currently affecting science communication, and the impact that the life sciences industry is having on our society. He draws parallels between the worlds of ‘big pharma’ and ‘big STM publishing’, since both face radical challenges from internet enabled consumers, and both have reason to be wary of the risks posed by new ways of working and communicating. As Basset points out, the two worlds are closely intertwined: “pharma customers represent 20 per cent of big STM sales … Similarly, big pharma is strictly dependent on scientific publishing for the research process, for the update of researchers’ knowledge and for the publicity of their products.”
Read the full article at:
Maceviciute E. (2013). Review of: Basset, Hervé, Stuart, David & Silber, Denise From Science 2.0 to Pharma 3.0 : Semantic search and social media in the pharmaceutical industry and STM publishing.. Oxford: Chandos Publishing, 2012. Information Research, 18(2), review no. R479 [Available at: http://informationr.net/ir/reviews/revs479.html%5D
“First, I was surprised by the introduction, in which the similarities between commercial scholarly publishing and big pharmaceutical drug production were outlined. (…) . This was a perfect opportunity to find out what is happening at present.
Indeed, I could not have chosed a better source even if I was looking for it very deliberately. The book is about what it actually says in the sub-title: the present developments in how the pharmaceutical industry uses social media and semantic search and comparison of it with the situation in publishing in science, technology and medicine (STM). (…)
Thus, the changes in health behaviour with regard to the use of social media and the alternative movements in scholarly communication are explored to provide a wide social context for both industries and both technologies. Again a number of interesting parallels are discovered by the authors...
Secondly, I was impressed by the team of authors who worked on the book. Their knowledge of the subject and understanding of respective industries, the level of control of vast literature and information is very impressive. I would not call this a popular book as it concentrates on quite specific matters, but for those interested in these subjects it would be a useful source...
Interesting findings given by several French students, about the power of blogging for young scientists:
- The transmission of knowledge is a difficult task. You need to multiply the initiatives, and that’s where the blog plays an important role
- PhD candidates have little free time, but it is probably the period in their careers when they have the most time to spend “informing the public
- blogging is about sharing findings, sharing your work, and creating a digital e-reputation
- Blogging also means improving one’s writing skills, editing speed, and scientific analysis, which are all valuable abilities when it comes to writing your thesis
- If you write and publish online, make it so that you’ll be read. Post your articles on Facebook, Twitter, or LinkedIn. E-mail your texts to people likely to read them.
Read the full article from:
Science Blogs and Your PhD. A trump card for your scientific career; Available from: http://www.knowtex.com/nav/science-blogs-and-your-phd-a-trump-card-for-your-scientific-career_40002
“We recently caught up with Hervé Basset, specialist librarian in the pharmaceutical industry and owner of the blog “Science Intelligence“, to talk about the inspiration behind his recent book entitled “From Science 2.0 to Pharma 3.0″, published by Chandos Publishing and available on Amazon.“
Read the full article on http://digimind.com/blog/experts/pharma-3-0/
“A monumental shift is happening that will impact the future of healthcare, according to an Ernst & Young report, which outlines a new approach to healthcare delivery, leading to the reinvention of commercial models within the pharmaceutical industry. (…)
The report, Progressions – The third place: Healthcare everywhere examines how several forces, including patent cliffs; reduced R&D productivity, pricing pressures, globalization and demographics have made the industry’s long-standing blockbuster business model increasingly outdated. These factors fueled a transition known as the move from Pharma 1.0, a vertically integrated blockbuster model to Pharma 2.0, which is the current model based on a more diversified market portfolios and a broader focus on bottom-line returns, not just top-line growth. The move to Pharma 3.0 won’t be automatic. (…)
“What we’re talking about at a very high level is a move to new healthcare system that is based on value and not volume,” (…)
Signs exist indicating that pharma companies are moving customer centricity (…)
Pharma 3.0 is also significant because it involves the transition from blockbuster drugs to more personalized medicine for smaller populations…
Read the full article:
Burns, Mia. Pharma moving toward more customer-centric models. MedAdNews-Pharmalive, online on February, 5th 2013. Available from:
For Pharma 3.0 models, read also:
From Science 2.0 to Pharma 3.0
Available at Chandos: http://www.woodheadpublishing.com/en/book.aspx?bookID=2767&ChandosTitle=1
“one study found that a primary care physician would have to read 341 relevant medical journals and 7,287 monthly articles, equaling more than 627 reading hours per month, just to stay current on all medical literature. But who has time when you’re treating patients?“